|
An Update on Potassium-Competitive Acid Blocker (PCAB) and Proton Pump Inhibitor (PPI) Prescribing
Recorded for 2024 National Conference
|
|
Facebook
LinkedIn
E-Mail
|
(835)
|
Activity DurationContent Expires: | July 15, 2025 (11:55 p.m. CT) CE for this activity will not be available after this date. | This CE activity was recorded for the 2024 AANP National Conference. | This activity includes closed captioning. |
Delivery Note: The content for this activity was previously presented during the 2024 AANP National Conference. If you already completed the content of this activity while attending the live or virtual conference, you should not complete this content a second time. Learners should only complete ONE delivery-method to earn credit. Completing multiple delivery options for the same activity is considered duplicate credit for the same content and will not be accepted by regulatory bodies. |
Overview An update on potassium-competitive acid blocker (PCAB) and proton pump inhibitor (PPI) prescribing for the Advanced Practice Provider. Proton pump inhibitors (PPI) are one of the most common prescribed medications, it is estimated that that over 100 million prescriptions for PPIs are filled annually. In 2023 PCABs, a new class of therapy had been approved. Up-to-date knowledge regarding acid blocker therapy remains essential in clinical practice. As an advanced practice provider, it is imperative to understand this new class of therapy and current data about PCAB/PPI safety so as to appropriately educate our patients. Objectives
- Evaluate indications and dosing of proton-pump inhibitor (PPI) and potassium-competitive acid blocker (PCAB) therapy.
- Discuss mechanism of action of PPI and PCAB therapy.
- Analyze the side effect profile and review current safety data of PPI and PCAB therapy.
Speaker Kimberly Kearns, MS, APRN, ANP-BC
Disclosure This program was planned in accordance with AANP CE Standards and Policies. The speaker has the following disclosures:- I am a speaker for Eli Lilly (IBD), Janssen (IBD), Nestlé Health Science, (C-diff), Salix (IBS, CIC) and Takeda Pharmaceuticals (IBD).
- I am on the advisory board for Ardelyx (IBS), Eli Lilly (IBD), Bristol Meyer Squibb (IBD), Janssen (IBD), Salix (IBS and CIC) and Pfizer Pharmaceuticals (IBD).
- I am a consultant for Janssen Pharmaceuticals and Takeda Pharmaceuticals for (IBD).
All relevant financial relationships have been mitigated. DisclaimerIndividuals who have contributed to the CE Center (content originally from the 2024 AANP National Conference) were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. CE Credit Instructions
- Read this activity description, including objectives and disclosures.
- Complete all educational content:
- OnDemand Presentations: Click the Play button to watch the activity video lecture. To get full credit for the learning activity portion, you must watch all of the video content.
- Click on the Additional Resources button to review all additional materials provided (handouts and any other downloadable resources).
- After completing all educational content, go to the Next Steps button:
- Submit the activity evaluation to receive full AANP CE/Rx credit.
- Click on the Get Certificate button. At the top of the certificate screen, use the provided dropdown menu and select AANP Certificate of Completion.
- A copy of your certificate of completion will display on the screen for you to print or save. A copy of the certificate will also be emailed to you.
- A copy of the certificate will be automatically added to your AANP CE Tracker.
Additional Information For questions or more information concerning this online CE activity, please visit the AANP Help Center to find answers to frequently asked questions and request assistance.
1 Contact Hour(s) of CE, All of which may be applied towards Pharmacology
|
|
Additional CE activities of interest
(OnDemand) Antibiotics And Infection in Acute Care: Update 2024
(OnDemand) Evaluation and Management of Classical and Atypical GERD
(OnDemand) Balancing Act: Strategies for Tackling Dizziness
(OnDemand) Pharyngitis, Sinusitis, Otitis Media, Otitis Externa across the lifespan
(OnDemand) Back Pain? Don't Misdiagnose This!
(OnDemand) 2024 ACIP Immunization Update: Latest best practices
(OnDemand) Infectious Disease Update 2024
(OnDemand) A Focus on Men’s Health: Erectile Dysfunction And Testosterone Deficiency
(OnDemand) Anorectal Evaluation: STIs, Hemorrhoids, Fissures
(OnDemand) I Think I Tore My Rotary Cup: Shoulder Evaluation for the Primary Care and Acute Care Provider
(OnDemand) Genitourinary Syndrome Of Menopause: How Do We Help Our Patients?
(OnDemand) Taming Thyroiditis: Post-partum, Infectious And Hashimoto’s Thyroiditis
|
|